Latest Advanced Prostate Cancer News2017-10-19T10:43:14-04:00

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a [...]

XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) [...]

By |February 6th, 2018|Categories: Advanced Prostate Cancer, Understanding Advanced Prostate Cancer|0 Comments
Go to Top